Resource Summary Report

Generated by RRID on Sep 6, 2026

Mouse anti-Human IgG1 Fc Secondary Antibody, HRP

RRID:AB_2534051
Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# A-10648, RRID:AB_2534051

Antibody Information

URL: http://antibodyregistry.org/AB_2534051

Proper Citation: Thermo Fisher Scientific Cat# A-10648, RRID:AB_2534051

Target Antigen: Human IgG1 Fc

Host Organism: mouse

Clonality: monoclonal secondary

Comments: Applications: IHC (1:500-1:2,000), ELISA (1:500-1:2,000), WB (1:500-1:2,000)

Antibody Name: Mouse anti-Human IgG1 Fc Secondary Antibody, HRP

Description: This monoclonal secondary targets Human IgG1 Fc

Target Organism: human

Clone ID: Clone HP6069

Defining Citation: PMID:9660461, PMID:27804292

Antibody ID: AB_2534051

Vendor: Thermo Fisher Scientific

Catalog Number: A-10648

Record Creation Time: 20231110T035523+0000

Record Last Update: 20260901T013230+0000

Ratings and Alerts

No rating or validation information has been found for Mouse anti-Human IgG1 Fc Secondary Antibody, HRP.

No alerts have been found for Mouse anti-Human IgG1 Fc Secondary Antibody, HRP.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Tam JCH, et al. (2025) Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses. Cell reports, 44(7), 116000.

Zhong J, et al. (2025) TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study. Cancer cell, 43(12), 2268.

Tobias J, et al. (2024) Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON). Clinical cancer research : an official journal of the American Association for Cancer Research, 30(18), 4044.

Chauvin C, et al. (2023) Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants. iScience, 26(3), 106124.

Honjo K, et al. (2021) Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. Cell reports. Medicine, 2(1), 100164.

King LB, et al. (2018) The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. Cell host & microbe, 23(1), 101.

Shivange G, et al. (2018) A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer. Cancer cell, 34(2), 331.